AR020768A1 - Proceso para preparar derivados de beta-alanina y los derivados de beta-alanina obtenidas con dicho proceso - Google Patents

Proceso para preparar derivados de beta-alanina y los derivados de beta-alanina obtenidas con dicho proceso

Info

Publication number
AR020768A1
AR020768A1 ARP990105130A ARP990105130A AR020768A1 AR 020768 A1 AR020768 A1 AR 020768A1 AR P990105130 A ARP990105130 A AR P990105130A AR P990105130 A ARP990105130 A AR P990105130A AR 020768 A1 AR020768 A1 AR 020768A1
Authority
AR
Argentina
Prior art keywords
beta
derivatives
alanine
alanina
prepare
Prior art date
Application number
ARP990105130A
Other languages
English (en)
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of AR020768A1 publication Critical patent/AR020768A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se trata de un proceso para la preparacion de derivados de beta-alanina de formula (I) en el cual R1 es un grupo amino protector, y R2 es un grupo acilo, ouna sal del mismo, que comprende: someter un compuesto de la formula (II) en la cual R1 es talcomo se definiera con anterioridad y R3 es carboxi protegido, ouna sal del mismo, a la reaccion de eliminacion del grupo protector carboxi y luego a la reaccion de acilacion del grupo amino. También se proponen losderivados de beta-alanina que seobt ienen con dicho proceso, particularmente el trihidrato de N-[(R)-1-[3-(4-piperidil)-propionil]-3-piperidil-carbonil]-2(S)-acetilamino-beta-alanina.
ARP990105130A 1998-10-12 1999-10-08 Proceso para preparar derivados de beta-alanina y los derivados de beta-alanina obtenidas con dicho proceso AR020768A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPP6465A AUPP646598A0 (en) 1998-10-12 1998-10-12 New processes for producing alpha-alanine derivative

Publications (1)

Publication Number Publication Date
AR020768A1 true AR020768A1 (es) 2002-05-29

Family

ID=3810687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990105130A AR020768A1 (es) 1998-10-12 1999-10-08 Proceso para preparar derivados de beta-alanina y los derivados de beta-alanina obtenidas con dicho proceso

Country Status (16)

Country Link
US (2) US6538007B1 (es)
EP (1) EP1121346A1 (es)
JP (1) JP2002527424A (es)
KR (1) KR20010075623A (es)
CN (1) CN1329595A (es)
AR (1) AR020768A1 (es)
AU (1) AUPP646598A0 (es)
BR (1) BR9914780A (es)
CA (1) CA2346433A1 (es)
CZ (1) CZ20011324A3 (es)
HK (1) HK1043120A1 (es)
HU (1) HUP0104067A3 (es)
TR (1) TR200101040T2 (es)
TW (1) TW490460B (es)
WO (1) WO2000021932A1 (es)
ZA (1) ZA200102781B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010051730A1 (en) * 1993-09-22 2001-12-13 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivative and a process for the preparation thereof
AUPQ570100A0 (en) * 2000-02-17 2000-03-09 Fujisawa Pharmaceutical Co., Ltd. Beta-alanine derivatives and their use as receptor antagonists
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
WO2005079863A1 (ja) 2004-02-25 2005-09-01 Astellas Pharma Inc. 血栓造影剤
CN105017134A (zh) * 2015-07-26 2015-11-04 陈吉美 一种4-吡啶丙烯酸的制备方法
JP7220653B2 (ja) 2016-11-08 2023-02-10 ブリストル－マイヤーズ スクイブ カンパニー アルファｖインテグリン阻害剤としてのピロールアミド
CN110078657A (zh) * 2019-04-10 2019-08-02 湖州复华春生物医药科技有限公司 一种手性3-氨基哌啶及其衍生物的合成方法
CN109970585A (zh) * 2019-04-29 2019-07-05 安徽安力肽生物科技有限公司 一种β-丙氨酸酯类化合物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2161155C2 (ru) * 1993-09-22 2000-12-27 Фудзисава Фармасьютикал Ко., Лтд Производные n-(3-пиперидинилкарбонил)-бета-аланина в качестве антагонистов фактора активации тромбоцитов (фат), способ получения, фармацевтическая композиция и способ лечения
CA2215106A1 (en) 1995-03-17 1996-09-26 Fujisawa Pharmaceutical Co., Ltd. N-acylpiperidinylcarbonylaminocarboxylic acids and their use as glycoprotein iib/iiia antagonists and fibrinogen-blood platelets binding inhibitors
WO1997033869A1 (en) * 1996-03-13 1997-09-18 Fujisawa Pharmaceutical Co., Ltd. N-[(r)-1-{3-(4-piperidyl)propionyl-3-piperidylcarbonyl]-2(s)-acetylamino-beta-alanine as fibrinogen receptor antagonist

Also Published As

Publication number Publication date
TW490460B (en) 2002-06-11
BR9914780A (pt) 2001-10-30
CA2346433A1 (en) 2000-04-20
AUPP646598A0 (en) 1998-11-05
EP1121346A1 (en) 2001-08-08
ZA200102781B (en) 2002-07-04
TR200101040T2 (tr) 2001-08-21
JP2002527424A (ja) 2002-08-27
HK1043120A1 (zh) 2002-09-06
HUP0104067A2 (hu) 2002-03-28
KR20010075623A (ko) 2001-08-09
CN1329595A (zh) 2002-01-02
US6538007B1 (en) 2003-03-25
CZ20011324A3 (cs) 2001-08-15
WO2000021932A1 (en) 2000-04-20
HUP0104067A3 (en) 2002-04-29
US20030114488A1 (en) 2003-06-19

Similar Documents

Publication Publication Date Title
EA200000871A1 (ru) Ингибиторы фосфолипазных ферментов
EA200100971A1 (ru) Новые соединения и композиции в качестве ингибиторов протеазы
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA199900593A1 (ru) ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
RU95104885A (ru) 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция
EA200100992A1 (ru) Ингибиторы фермента impdh
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
EA200400944A1 (ru) Замещенные производные тетрациклина, фармацевтическая композиция и способ лечения субъекта с их использованием
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200401282A1 (ru) Пиридиноилпиперидины как агонисты 5-ht1f
ES2188194T3 (es) 1,8-naftiridin-4(1h)-onas sustituidas como inhibidores de la fosfodiesterasa 4.
EA199900448A1 (ru) Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos
EA200200253A1 (ru) Ингибиторы клеточной адгезии
FI954944A0 (fi) Indolijohdannaisia 5-HT1-kaltaisina agonisteina käytettäväksi migreenin hoitoon
EA200000804A1 (ru) Мета-азациклические соединения аминобензойной кислоты и их производные, являющиеся ингибиторами интегрина
ATE170845T1 (de) Plättchenaggregationsinhibitoren
ES2105286T3 (es) Derivados de etanolamina que tienen actividades simpatomimetica y anti-polaquiuria.
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
AR020768A1 (es) Proceso para preparar derivados de beta-alanina y los derivados de beta-alanina obtenidas con dicho proceso
EA200000320A1 (ru) Изохинолины в качестве ингибиторов урокиназы
NZ302072A (en) 1,3-diamino propyl stereomeric derivatives and organic acid and inorganic salts of their amine intermediates in the preparation of retroviral protease inhibitors
DE60113407D1 (de) Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten
EA200100297A1 (ru) Моногидрат гидробромида элетриптана
BR9912684A (pt) Composto de fórmula (i), composição farmacêutica compreendendo o composto, método, processo e seu uso
EA200100213A1 (ru) Способ синтеза производных (1h)-бензо[c]хинолизин-3-онов